BTIG analyst Gregory Lewis maintained a Buy rating on Blue Bird (BLBD – Research Report) today and set a price target of $45.00. The company’s ...

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday, February 12, 2025. The firm expects ...

HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...

Performant Healthcare, Inc. (Nasdaq: PHLT) ("Performant"), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, announced today that it will ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

StockNews.com upgraded shares of Boot Barn (NYSE:BOOT – Free Report) from a sell rating to a hold rating in a research report ...

Full-year FY 2025 revenue guidance was raised to $463M-$475M, up from $462M-$472M, while adjusted EBITDA guidance increased to $28.5M-$31M from $28M-$30M. Management anticipates stronger revenue ...

BTIG analyst Lance Jessurun reaffirmed a Neutral rating on PayPal (NASDAQ:PYPL) stock, expressing caution ahead of the ...

BTIG Research has recently reduced Ginkgo Bioworks Holdings Inc (DNA) stock to Sell rating, as announced on May 15, 2024, according to Finviz. Earlier, on May 10, 2024, William Blair had reduced the ...

Market technician Jonathan Krinsky analyzes the shift in market leadership from technology to healthcare amid recent ...